Novo Nordisk has initiated legal proceedings against Eli Lilly, alleging that the latter’s advertising campaigns for weight-loss drugs Zepbound and Mounjaro are misleading. The lawsuit, filed in the U.S. District Court for New Jersey, contends that Lilly’s advertisements utilize outdated clinical trials to compare the highest doses of its medications with lower doses of Novo’s Wegovy and Ozempic, thereby presenting a skewed portrayal of efficacy.
John Kuckelman, Novo’s senior vice president and group general counsel, stated that the advertisements “are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines.” He emphasized that this practice misleads consumers by omitting critical clinical context.
In response, Lilly’s spokesperson, Michael Jamison, defended the company’s advertising practices, asserting that they are “truthful, transparent, and grounded in the most direct scientific evidence available.” He added that Lilly will “continue to focus on the science and defend against this lawsuit vigorously.”
The legal action underscores the intensifying competition in the GLP-1 receptor agonist market, a class of drugs used for weight management and type 2 diabetes treatment. Both companies have been vying for dominance, with Novo’s Wegovy and Ozempic facing off against Lilly’s Zepbound and Mounjaro. The market is projected to reach $100 billion in the U.S. by 2030, reflecting the high stakes involved.
Novo Nordisk is seeking a court order to compel Lilly to withdraw the contested advertisements and to conduct a corrective advertising campaign. The company has indicated that it will pursue a preliminary injunction if Lilly does not voluntarily remove the ads. Additionally, Novo is seeking damages, including profits that may be attributed to the alleged misleading advertisements.
This lawsuit highlights the critical importance of accurate and current information in pharmaceutical advertising, especially in a rapidly evolving market where new formulations and dosages are continually being developed and approved.